文献速递白血病

Vodobatinib 用于对多线既往治疗耐药或不耐受的费城染色体阳性慢性髓性白血病患者:一项开放标签、多中心、1/2 期试验

Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial.
PubMed 文献 · Lancet Haematol · 2025-02-07

这项开放标签多中心1/2期试验在10个国家28个中心纳入78例既往接受至少三种TKI(包括ponatinib和asciminib)的Ph阳性慢性髓性白血病患者,口服vodobatinib 12-240 mg每日一次。2例240 mg剂量组出现剂量限制性毒性,204 mg被确定为最大耐受剂量;慢性期患者主要细胞遗传学缓解率为70%(44/63)。

要点

  • 204 mg被确定为vodobatinib的最大耐受剂量。
  • 慢性期患者主要细胞遗传学缓解率为70%(44/63)。
  • 2期研究统计学效能不足,需进一步开展3期随机对照试验。

核心结论

  • 1期和2期汇总分析显示vodobatinib在既往接受多线TKI(包括ponatinib和asciminib)的晚期慢性髓性白血病患者中具有临床意义的抗白血病活性且安全性可耐受。
  • 2期研究统计学效能不足,需进一步在3期随机对照试验及疾病更早期治疗场景中研究。

研究设计与样本

  • 开放标签、多中心、1/2期试验,在10个国家(比利时、法国、匈牙利、印度、意大利、罗马尼亚、韩国、西班牙、英国和美国)的28个临床中心开展。
  • 纳入年龄≥18岁、ECOG体能状态≤2的Ph阳性慢性髓性白血病或急性淋巴细胞白血病患者(急性淋巴细胞白血病仅限1期)。
  • 1期纳入既往接受至少三种TKI或无其他可用治疗选择的患者;2期要求对至少三种TKI耐药或不耐受(或两者兼有)且失去反应,并既往使用过ponatinib。
  • 两期均排除存在Thr315Ile突变的患者。
  • 患者每日一次自行口服vodobatinib(12-240 mg),每28天为一个治疗周期,最长60个月(即65个周期)。

主要发现

  • 78例患者中慢性期66例(85%)、加速期8例(10%)、急变期4例(5%);男性43例(55%),女性35例(45%);中位年龄59.0岁(IQR 47.0-66.0);中位随访22.3个月(IQR 11.1-43.9)。
  • 2例接受240 mg vodobatinib的患者出现剂量限制性毒性(1例3级呼吸困难,1例2级液体潴留),因此204 mg被认为最大耐受剂量。
  • 73例(94%)患者出现至少一种治疗中出现的不良事件,大多数为血液学或胃肠道事件且严重程度为2级或以下。
  • 47例(60%)患者发生3级或以上治疗中出现的不良事件,包括血小板减少(14例[18%])、中性粒细胞减少(10例[13%])、贫血(9例[12%)和脂肪酶升高(8例[10%])。
  • 研究期间7例(9%)患者死亡;临床研究者认为其中1例死亡与治疗相关。

临床怎么用

  • 作者认为vodobatinib在既往接受多线TKI(包括ponatinib和asciminib)的晚期慢性髓性白血病患者中显示出临床意义的抗白血病活性和可耐受的安全性,填补了未满足的临床需求。
  • 作者指出2期研究统计学效能不足,需进一步开展3期随机对照试验及在疾病更早期治疗场景中研究。

局限性

  • 2期研究统计学效能不足。
  • 2期入组因招募相关困难于2023年6月22日提前关闭。
  • 需进一步在3期随机对照试验及疾病更早期治疗场景中研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resistance or intolerance to the available tyrosine kinase inhibitors (TKIs) remains a treatment challenge for patients with chronic myeloid leukaemia. We aimed to report the safety, antileukaemic activity, and pharmacokinetics of oral vodobatinib, a novel selective BCR::ABL1 TKI, in patients with Philadelphia chromosome-positive (Ph-positive) chronic myeloid leukaemia who previously received at least three TKIs, including ponatinib and asciminib. METHODS: This open-label, multicentre, phase 1/2 trial was conducted at 28 clinical sites across ten countries (Belgium, France, Hungary, India, Italy, Romania, South Korea, Spain, UK, and the USA). Patients aged 18 years or older with Ph-positive chronic myeloid leukaemia or acute lymphoblastic leukaemia (eligible only for the phase 1 study), and an Eastern Cooperative Oncology Group performance status of 2 or lower were eligible. Phase 1 included patients who previously received at least three TKIs or had no other available treatment options. Phase 2 required patients to have treatment resistance or intolerance (or both) with loss of response to at least three TKIs and previous ponatinib use. A key exclusion criterion for both phases was presence of the Thr315Ile mutation. Patients self-administered oral vodobatinib (12-240 mg) once per day for each 28-day treatment cycle and for up to 60 months (ie, 65 cycles) unless patient discontinuation due to adverse events, progressive disease, lost to follow-up, or death. The primary endpoints were to determine the maximum tolerated dose (based on dose-limiting toxicities in phase 1) and antileukaemic activity of vodobatinib (ie, major cytogenetic response for chronic-phase and major haematological response for accelerated-phase or blast-phase in phase 2). Assessment of vodobatinib safety, activity, and pharmacokinetics were determined based on the pooled analysis of data from the phase 1 and 2 studies. This trial is registered with ClinicalTrials.gov, NCT02629692 (active). At data cutoff (July 15, 2023), phase 2 enrolment was closed early on June 22, 2023, due to recruitment-related challenges. FINDINGS: 78 patients were enrolled and received at least one vodobatinib dose (safety and efficacy analysis set). Between April 6, 2017, and June 20, 2023, phase 1 enrolled 58 patients and phase 2 enrolled 20 patients between March 3, 2020, and March 29, 2023. We included 66 (85%) patients with chronic-phase, eight (10%) with accelerated-phase, and four (5%) with blast-phase chronic myeloid leukaemia. 43 (55%) of 78 patients were male and 35 (45%) were female. The median age was 59·0 years (IQR 47·0-66·0). The median follow-up was 22·3 months (IQR 11·1-43·9). Two patients receiving vodobatinib 240 mg had dose-limiting toxicities (one had grade 3 dyspnoea and the other had grade 2 fluid overload), thus the 204 mg dose was considered to be the maximum tolerated dose. 73 (94%) patients had one or more treatment-emergent adverse events, with most events being haematological or gastrointestinal that were grade 2 or lower in severity. Grade 3 or higher treatment-emergent adverse events occurred in 47 (60%) patients and included thrombocytopenia (14 [18%]), neutropenia (10 [13%]), anaemia (nine [12%]), and increased lipase (eight [10%]). Seven (9%) patients died during the study; one death was considered related to treatment by the clinical investigator. At data cutoff, major cytogenetic response was observed in 44 (70%) of 63 patients with chronic-phase chronic myeloid leukaemia, of which 12 (75%) of 16 patients in the phase 2 study had major cytogenetic response. For patients with accelerated-phase chronic myeloid leukaemia, six (86%) of seven patients had a major haematological response (median duration 17·8 [IQR 10·2-24·3]) at data cutoff; major haematological response was observed in three (100%) evaluable patients in the phase 2 study. Major haematological response was reached by two (50%) of four patients with blast-phase chronic myeloid leukaemia and the median duration of response was 6·2 months (IQR 3·2-9·3); no blast-phase patients were enrolled in the phase 2 study. INTERPRETATION: Pooled analysis of the phase 1 and 2 studies showed clinically meaningful antileukaemic activity of vodobatinib and a tolerable safety profile in patients with advanced chronic myeloid leukaemia who previously received multiple TKIs, including ponatinib and asciminib, addressing an otherwise unmet clinical need. The phase 2 study was statistically underpowered and warrants further investigation in a phase 3, randomised controlled trial and in an earlier treatment setting of the disease. FUNDING: Sun Pharma Advanced Research Company.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Cortes JE, Kim DW, Saikia T, et al. Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2025. PMID: 39929221. doi:10.1016/S2352-3026(24)00354-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。